ATE192925T1 - Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen - Google Patents

Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen

Info

Publication number
ATE192925T1
ATE192925T1 AT95907382T AT95907382T ATE192925T1 AT E192925 T1 ATE192925 T1 AT E192925T1 AT 95907382 T AT95907382 T AT 95907382T AT 95907382 T AT95907382 T AT 95907382T AT E192925 T1 ATE192925 T1 AT E192925T1
Authority
AT
Austria
Prior art keywords
pdgf
compounds
activity
inhibit
derived growth
Prior art date
Application number
AT95907382T
Other languages
English (en)
Inventor
Klaus Peter Hirth
Donna Pruess Schwartz
Elaina Mann
Laura Kay Shawver
Gyorgy Keri
Istvan Szekely
Tamas Bajor
Janis Haimichael
Laszlo Orfi
Alex Levitzki
Aviv Gazit
Axel Ullrich
Reiner Lammers
Fairooz F Kabbinavar
Dennis J Slamon
Cho Peng Tang
Original Assignee
Sugen Inc
Biosignal Ltd
Yissum Res Dev Co
Max Planck Gesellschaft
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Biosignal Ltd, Yissum Res Dev Co, Max Planck Gesellschaft, Univ California filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE192925T1 publication Critical patent/ATE192925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/912—Cancer cell repair
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95907382T 1994-01-07 1995-01-06 Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen ATE192925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/179,570 US5700823A (en) 1994-01-07 1994-01-07 Treatment of platelet derived growth factor related disorders such as cancers
PCT/US1995/000363 WO1995019169A2 (en) 1994-01-07 1995-01-06 Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor

Publications (1)

Publication Number Publication Date
ATE192925T1 true ATE192925T1 (de) 2000-06-15

Family

ID=22657130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907382T ATE192925T1 (de) 1994-01-07 1995-01-06 Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen

Country Status (13)

Country Link
US (5) US5700823A (de)
EP (2) EP1000617A3 (de)
CN (1) CN1065744C (de)
AT (1) ATE192925T1 (de)
AU (1) AU690958B2 (de)
CA (1) CA2180658C (de)
DE (1) DE69517054T2 (de)
DK (1) DK0804191T3 (de)
ES (1) ES2149966T3 (de)
GR (1) GR3034215T3 (de)
IL (1) IL112277A (de)
PT (1) PT804191E (de)
WO (1) WO1995019169A2 (de)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CA2166871A1 (en) * 1993-07-29 1995-02-09 Neill A. Giese Receptor function assays
US5952355A (en) * 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5958942A (en) * 1994-07-15 1999-09-28 Takeda Chemical Industries, Ltd. Tricyclic nitrogen ring compounds, their production and use
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
EP0824525B1 (de) * 1995-04-27 2001-06-13 AstraZeneca AB Chinazolin derivate
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996035665A1 (en) * 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US5834173A (en) * 1995-12-22 1998-11-10 Eastman Kodak Company Filter dyes for photographic elements
EP0762198B1 (de) * 1995-08-02 2000-10-04 Eastman Kodak Company Filterfarbstoffe enthaltende photographische Elemente
US5895813A (en) * 1995-10-13 1999-04-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Diagnosis and treatment of TKA-1 related disorders
US5922842A (en) * 1995-10-13 1999-07-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tyrosine kinase associated polypeptides
US5945523A (en) * 1995-10-13 1999-08-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Diagnosis and treatment of TKA-1 related disorders
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US5695917A (en) * 1995-11-22 1997-12-09 Eastman Kodak Company Combination of yellow filter dye and 4-equivalent pyrazolone magenta coupler
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU3577997A (en) * 1996-06-24 1998-01-14 Irori Solid phase tyrphostin library linked to matrices with memories
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
CA2214393A1 (en) * 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6074640A (en) * 1997-10-30 2000-06-13 Uab Research Foundation Enhancement of tumor cell radiosensitivity using single chain intracellular antibodies
US6051565A (en) 1997-04-26 2000-04-18 International Phytochemistry Research Labs, Ltd. Farnesyl-protein transferase inhibitors
AU7687998A (en) * 1997-05-19 1998-12-11 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP0903344B1 (de) * 1997-08-21 2011-01-26 Shiseido Co., Ltd. Chinazolin-4-on Derivate, deren Herstellung und deren Verwendung als Haarwuchsmittel oder in äusserlich anzuwendenden Hautpflegemitteln
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
KR100579355B1 (ko) * 1997-10-03 2006-05-12 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 스티릴 설폰 항암제
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US5932580A (en) * 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
WO1999032627A2 (en) * 1997-12-23 1999-07-01 The United States Of America, Represented By The Secretary, Department Of Health And Human Services The protein tyrosine kinase substrate lat and its use in the identification of (ant)agonists of the kinase
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO1999054286A2 (en) * 1998-04-17 1999-10-28 Parker Hughes Institute Btk inhibitors and methods for their identification and use
HU226567B1 (en) * 1998-04-27 2009-04-28 Biostatin Gyogyszerkutato Fejl Use of phenylhydrazon derivates for the preparation of medicaments for the inhibition of neurogenic and non-neurogenic inflammations and for the alleviation of pain
ATE489108T1 (de) * 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
WO2000069909A1 (en) 1999-05-14 2000-11-23 The United States Of America Through The Department Of Veterans Affairs Isolation and characterization of epidermal growth factor related protein
US6566395B1 (en) * 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001021160A2 (en) * 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
US6610718B2 (en) * 1999-12-16 2003-08-26 Teva Pharmaceutical Industries Ltd. Processes for making- and a new crystalline form of- leflunomide
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
RU2277531C9 (ru) * 2000-04-13 2006-11-20 Эйч Эс Си Рисерч Энд Дивелопмент Лимитед Партнершип Новые соединения для модулирования клеточной пролиферации
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
DE60226855D1 (de) 2001-04-05 2008-07-10 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
IL159270A0 (en) * 2001-06-14 2004-06-01 Yissum Res Dev Co Non-myeloablative tolerogenic treatment with tyrphostins
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
US20030149038A1 (en) * 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AU2003210983A1 (en) * 2002-02-11 2003-09-04 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
US20030181377A1 (en) * 2002-02-12 2003-09-25 Vanderbilt University Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
PT1476192E (pt) * 2002-02-14 2007-07-26 Dana Farber Cancer Inst Inc Métodos e composições para tratar condições hierproliferativas
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1513820A4 (de) 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
WO2004015082A2 (en) * 2002-08-09 2004-02-19 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
US20050043344A1 (en) * 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
MXPA05006587A (es) * 2002-12-20 2005-12-14 Pharmacia Corp Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
JP2006513218A (ja) * 2002-12-20 2006-04-20 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物
DE10311763A1 (de) * 2003-03-18 2004-10-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 2-Cyan-3-hydroxy-N-(phenyl)but-2-enamiden
US6894184B2 (en) * 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
WO2004096795A2 (en) * 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20040224343A1 (en) * 2003-05-06 2004-11-11 Biochain Inc. Methods and products to enhance interactions among molecules
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
ME00541B (de) * 2003-05-23 2011-10-10 Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
EP1654220A4 (de) * 2003-07-30 2006-10-25 Hospital For Sick Children Verbindungen zur modulierung der zellproliferation
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
EP1691800A4 (de) * 2003-11-21 2009-03-18 Univ Newcastle Res Ass Verfahren und mittel zur hemmung von dynaminabhängiger endozytose
PT1701941E (pt) * 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US7598419B2 (en) * 2004-03-26 2009-10-06 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US20070197538A1 (en) * 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
US7705042B2 (en) * 2004-10-22 2010-04-27 Janssen Pharmaceutica Nv Class of arylamide compounds useful as inhibitors of c-fms kinase
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
KR20070113286A (ko) 2005-04-14 2007-11-28 에프. 호프만-라 로슈 아게 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
EP1746087A1 (de) * 2005-07-21 2007-01-24 Universitaet Regensburg 3-Indolylmethylen-Derivate mit cytostatischer Wirkung
US20080003219A1 (en) * 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
AU2006313701B2 (en) * 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ATE489380T1 (de) * 2006-02-10 2010-12-15 Amgen Inc Hydratformen von amg706
PL2514742T3 (pl) * 2006-03-31 2015-07-31 Univ Texas Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym
US20100292229A1 (en) * 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
WO2008021211A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
MX2009006077A (es) * 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
KR100933559B1 (ko) * 2007-10-01 2009-12-23 재단법인서울대학교산학협력재단 ３Ｈ-퀴나졸린-４-온 유도체를 함유하는 Ｈｓｐ９０ 억제제및 이를 이용한 항암제
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5675606B2 (ja) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011004282A2 (en) 2009-07-09 2011-01-13 Alembic Limited Novel polymorphic form of teriflunomide salts
JP2013505213A (ja) 2009-09-18 2013-02-14 サノフイ 改善された安定性を有する（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミド錠製剤
WO2011041731A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
WO2011041737A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Gain-of-function bcl-2 inhibitors
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012110911A1 (en) 2011-02-18 2012-08-23 Alembic Pharmaceuticals Limited Novel polymorphic form of teriflunomide
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
WO2012136120A1 (zh) * 2011-04-02 2012-10-11 中国人民解放军军事医学科学院毒物药物研究所 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
CN107245056A (zh) * 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
EP2755657B1 (de) 2011-09-14 2017-11-29 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
EP2806874B1 (de) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxalin-oxy-phenyl derivate als Kinase-Inhibitoren
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2890696A1 (de) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinonverbindungen und derivate davon
CN102786437A (zh) * 2012-09-06 2012-11-21 中国药科大学 一种特立氟胺的制备方法
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
KR102948178B1 (ko) 2013-07-12 2026-04-10 아스텔라스 유에스 엘엘씨 안과적 질환을 치료하거나 예방하기 위한 방법
CN103575905A (zh) * 2013-10-12 2014-02-12 中国人民解放军第三军医大学第一附属医院 血小板源性生长因子受体β检测试剂盒及其用途
KR20160079123A (ko) 2013-11-22 2016-07-05 젠자임 코포레이션 신경변성 질병을 치료하기 위한 신규한 방법
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR102703498B1 (ko) 2015-09-23 2024-09-04 얀센 파마슈티카 엔브이 신규 화합물
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CA3048217A1 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES2905676T3 (es) 2017-05-22 2022-04-11 Amgen Inc Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
CN108642130B (zh) * 2018-03-29 2021-10-15 浙江工业大学 一种酪氨酸酚裂解酶高活力菌株的高通量筛选方法
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3790886B1 (de) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c-inhibitoren zur behandlung von krebs
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
TW202043199A (zh) * 2019-01-30 2020-12-01 日商日產化學股份有限公司 醯肼化合物及激酶抑制劑
EP3930845A1 (de) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclische heterocyclyl-verbindungen und ihre verwendung
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式
CN110128308B (zh) * 2019-06-21 2021-04-30 利尔化学股份有限公司 α-烷氧基亚甲基-β-二羰基化合物的制备方法
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
CA3147272A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114302880B (zh) 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
CN114786777A (zh) 2019-11-04 2022-07-22 锐新医药公司 Ras抑制剂
PE20221277A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
CA3158188A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
KR102900581B1 (ko) * 2020-10-15 2025-12-16 가부시끼가이샤 레조낙 플루오로-2-부텐의 보관 방법
EP4267250A1 (de) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1-inhibitoren und verwendungen davon
EP4334324A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250017889A1 (en) * 2021-10-15 2025-01-16 The Curators Of The University Of Missouri Inhibitors of p1b-type atpases
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN116063238B (zh) * 2022-01-21 2025-09-19 上海交通大学 一种喹喔啉化合物及其制备方法
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN116924938B (zh) * 2022-04-02 2025-10-31 江苏康缘药业股份有限公司 一种特立氟胺的制备方法
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4601644A1 (de) 2022-10-14 2025-08-20 Black Diamond Therapeutics, Inc. Verfahren zur behandlung von krebs mit isochinolin- oder 6-azachinolinderivaten
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (de) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Makrocyclische ras-inhibitoren
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
SE8600260D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US4954876A (en) * 1988-08-01 1990-09-04 Sundstrand Corporation Hermetically sealed compression bonded circuit assembly having flexible walls at points of application of pressure for compression bonding circuit elements
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
ES2102367T3 (es) * 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
WO1992002444A1 (en) * 1990-08-08 1992-02-20 The Dow Chemical Company Compressive strength improvement of fibers by means of radial restraint
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2109515A1 (en) * 1991-05-29 1992-11-30 Robert L. Dow Dihydroxyindanone tyrosine kinase inhibitors
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
AU6910994A (en) * 1993-05-14 1994-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease

Also Published As

Publication number Publication date
IL112277A0 (en) 1995-05-26
EP0804191B1 (de) 2000-05-17
CN1065744C (zh) 2001-05-16
WO1995019169A2 (en) 1995-07-20
US5932602A (en) 1999-08-03
PT804191E (pt) 2000-10-31
DE69517054D1 (de) 2000-06-21
EP0804191A1 (de) 1997-11-05
ES2149966T3 (es) 2000-11-16
AU1563395A (en) 1995-08-01
EP1000617A2 (de) 2000-05-17
US5958959A (en) 1999-09-28
DE69517054T2 (de) 2001-01-18
US5990141A (en) 1999-11-23
IL112277A (en) 2004-03-28
US5700823A (en) 1997-12-23
CN1128496A (zh) 1996-08-07
EP1000617A3 (de) 2004-12-29
CA2180658C (en) 2000-03-28
WO1995019169A3 (en) 1996-02-15
DK0804191T3 (da) 2000-09-25
GR3034215T3 (en) 2000-12-29
CA2180658A1 (en) 1995-07-20
US5700822A (en) 1997-12-23
AU690958B2 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
DE69517054D1 (de) Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE283054T1 (de) Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
DE69711894D1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
GEP20002145B (en) Stem Cell Factor
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DE69132605D1 (de) Herstellung von Enzymen in Samen und ihre Verwendung
Chang et al. Expression of nitric oxide synthases in keratinocytes after UVB irradiation
ATE220400T1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
DE69332353D1 (de) Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs
NO961478D0 (no) Levobupivacaine anvendelig for kontroll av kronisk smerte
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE98488T1 (de) Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit beta-blockern oder bradycardica.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
IL94947A0 (en) 3-methoximinopropionic acid esters,their manufacture and their use as fungicides
DE3362725D1 (en) Carbamyloxybenzhydrole derivatives, process for their preparation and pharmaceutical compositions containing them
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
NZ335057A (en) Pentaerythritol derivatives, their production and use and intermediates for their synthesis
ATE190628T1 (de) Zusammensetzungen von wachstumsfaktoren, herstellung und verwendung
DE3786705D1 (de) Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.
Matsumoto et al. Stimulation of bone collagenase synthesis by mouse fibrosarcoma in resorbing bone in vitro culture
BINDMAN et al. “Facilitation” and “Reversal of Response” of Neurones in the Cerebral Cortex

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee